Typbar TCV Typhoid Vaccine Description
Typbar TCV is a vaccine containing polysaccharide of Salmonella typhi Ty2 conjugated to Tetanus Toxoid.
Vi Capsular polysaccharide of Salmonella typhi alone elicits B cell responses. The conjugation of bacterial polysaccharides to a protein carrier provides foreign peptide antigens presented to the immune system eliciting antigen-specific CD4+ Th cells, referred to as T-dependent antibody responses. A hallmark of T-dependent responses, which are also elicited by toxoid, is to induce both higher-affinity antibodies and long-term immune memory.
Results from a human challenge study carried out at the University of Oxford have demonstrated that the vaccine is safe, immunogenic, and prevents up to 87.1% of infections when using real-life definitions of typhoid fever.
Typbar TCV has been recommended by the experts at the WHO-Strategic Advisory Group for routine immunizations and is WHO prequalified.
Bharat Biotech is a pioneering biotechnology company known for its world-class R&D and manufacturing capabilities.
Typbar TCV Typhoid Vaccine Indication
Typbar TCV is indicated as a preventative vaccine against Typhoid, which Salmonella Typhi and Paratyphi cause.
Typbar TCV is the only approved vaccine for children and infants less than 2 years of age.
Typbar TCV Typhoid Vaccine Dosage
The WHO recently recommended that routine childhood immunization programs include Typbar TCV as a single intramuscular dose for primary vaccination of infants and children from 6 months of age.
It is also recommended for adults ≤45 years of age and in catch-up campaigns in children ≤15 years of age in typhoid-endemic regions.
Typbar TCV Typhoid Vaccine News
February 12, 2021 - U.S. CDC reports Extensively Drug-Resistant Salmonella Typhi Infections Among U.S. Residents Without International Travel.
February 1, 2021 - The next step: Lifesaving typhoid conjugate vaccines reach Punjab province, Pakistan. For the next two weeks, vaccination teams will be in Islamabad and 12 districts of Punjab province to vaccinate nearly 12.7 million children between the ages of 9 months to 15 years against typhoid. By keeping children protected against typhoid diseases, we help keep children in school and spare families the economic hardship that comes with a typhoid diagnosis and treatment.
January 4, 2021- How a scientist's return kickstarted Bharat Biotech's journey. The company also developed and launched Typbar TCV, the world’s first clinically-proven and WHO pre-qualified typhoid conjugate vaccine (TCV), which can be administered to even a six-month-old.
September 30, 2020 - Travel Alert: Extensively Drug-Resistant Typhoid Fever in Pakistan. The CDC recommends that all travelers (even short-term travelers) to South Asia, including Pakistan, be vaccinated against typhoid fever before travel.
January 3, 2018 - Typbar TCV from Bharat Biotech, World’s First Typhoid Conjugate Vaccine Prequalified by WHO. This enables the procurement and supplies of this life-saving vaccine to UNICEF, Pan-American Health Organization (PAHO), and GAVI-supported countries. Typbar TCV® has been evaluated in Human Challenge Studies at Oxford University, and typhoid conjugate vaccines have been recommended by WHO’s Strategic Advisory Group of Experts on Immunization (WHO-SAGE).
Typbar TCV Typhoid Vaccine Clinical Trials
Clinical Trial NCT03933098: Immune Non-inferiority and Safety of a Vi-DT Typhoid Conjugate Vaccine Last Update Posted on April 22, 2020. This is a Multicenter, observer-blinded, randomized, Active controlled, Phase 3 study in healthy 6 months to 45 years aged Nepalese at the time of the first vaccine dose.
Clinical Trial NCT03600025: Cellular Immune Responses in Typhoid Fever Patients and Vaccinees (Recruiting). This Phase 1 clinical trial aims to understand further the role of mucosal-associated invariant T cell (MAIT) and natural killer (NK) cell responses in typhoid fever or following vaccination.